TARPLIN, DOWNS & YOUNG, LLC for ASTRAZENECA
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
**see addendum pagePL 111-148 The Patient Protection and Affordable Care Act, implementation, health care reform, drug importation, follow-on biologics, 340b, comparative effectiveness, gift disclosure PL 112-144 The Food and Drug Administration Safety and Innovation Act, implementation ***, no specific bills, PDUFA, antimicrobial resistance, importation, companion diagnostics, user fee sequester
| Lobbyist | Covered position, as disclosed |
|---|---|
| RAISSA H DOWNS | — |
| MICHELLE P EASTON | — |
| ISAAC A FORDJOUR | — |
| LINDA E TARPLIN | — |
| JENNIFER B YOUNG | — |
Medicare/Medicaid MMM
**see addendum pagePL 111-148 The Patient Protection and Affordable Care Act, PL 111-152 - The Reconciliation Act of 2010, implementation, Medicare and Medicaid Drug Reimbursement, 340b, Innovation Center H.R. 351/S. 351 Protecting Seniors' Access to Medicare Act of 2013, IPAB repeal H.R. 2810 Medicare Patient Access and Quality Improvement Act of 2013, SGR S. 1871 - SGR Repeal and Medicare Beneficiary Access Act of 2013 ***, no specific bill(s), Medicare and Medicaid Drug Reimbursement, Medicaid Rebate, Medicare Part D, Non-Interference, health care reform implementation, AMP, Sunshine, conditions of participation
| Lobbyist | Covered position, as disclosed |
|---|---|
| RAISSA H DOWNS | — |
| MICHELLE P EASTON | — |
| ISAAC A FORDJOUR | — |
| LINDA E TARPLIN | — |
| JENNIFER B YOUNG | — |
Pharmacy PHA
**see addendum pagePL 112-144 - The Food and Drug Administration Safety and Innovation Act, implementation H.R. 2186 - Valid Compounding Act S. 959 - Pharmaceutical Compounding Quality and Accountability Act, track and trace H.R. 1919 - Safeguarding America's Pharmaceuticals Act of 2013, track and trace H.R. 3204 The Drug Quality and Security Act H.R. 2725, S. 1413 - Safety Over Sequester Act, user fee sequester relief ***, no specific bill(s), Import Safety, Prescription Drug User Fee Act renewal, drug development policy, drug shortages, supply chain integrity, patent settlements, user fee sequester relief
| Lobbyist | Covered position, as disclosed |
|---|---|
| RAISSA H DOWNS | — |
| MICHELLE P EASTON | — |
| ISAAC A FORDJOUR | — |
| LINDA E TARPLIN | — |
| JENNIFER B YOUNG | — |
Budget/Appropriations BUD
**see addendum pagebudget resolution, reconciliation, deficit reduction, debt ceiling, government shutdown, Continuing Resolution H.J.Res. 59, Continuing Appropriations Resolution, 2014
| Lobbyist | Covered position, as disclosed |
|---|---|
| RAISSA H DOWNS | Prin. Dep. Asst. Sec. for Leg. - HHS; Dep. Asst. |
| MICHELLE P EASTON | Chief Health Counsel, Sen. Cmte. On Finance; |
| ISAAC A FORDJOUR | — |
| LINDA E TARPLIN | Congressman Billy Tauzin |
| JENNIFER B YOUNG | Asst. Sec. for Leg. - HHS; Dep. Asst. Sec. for Leg. |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.